Researchers Investigate Whether At-Home Brain Stimulation Devices Could Reduce Reliance on Antidepressants

On December 8, 2025, the FDA granted premarket approval to the Flow Neuroscience FL-100, a headset that delivers weak electrical current to the brain through the scalp — making it the first at-home brain stimulation device cleared to treat major depressive disorder in the United States [1][2]. The device, expected to cost between $500 and $800 and become available by prescription in the second quarter of 2026, has been hailed by supporters as a long-overdue non-pharmaceutical option for the roughly 11.4% of American adults currently taking prescription medication for depression [3][4].

But behind the headlines lies a more complicated picture: an evidence base marked by modest effect sizes, a pivotal Lancet trial that found no benefit over placebo, industry-funded research driving regulatory decisions, and an absence of long-term data on what happens when patients swap pills for electrodes.

The Scale of the Problem

Depression treatment in the United States is dominated by antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs) — drugs like sertraline (Zoloft), escitalopram (Lexapro), and fluoxetine (Prozac) that increase serotonin levels in the brain. According to a 2025 CDC data brief, 11.4% of U.S. adults took prescription medication for depression in 2023, with women (15.3%) more than twice as likely as men (7.4%) to do so [3]. Usage was highest among white non-Hispanic adults (14.3%) and those living below the poverty line (14.8%) [3].

Source: CDC NCHS Data Brief #528

Data as of Apr 1, 2025CSV

The global antidepressant market was valued at approximately $16.9 billion in 2025, with SSRIs commanding roughly 55% of market share [5]. Generic SSRIs remain among the most affordable prescription drugs available, with monthly costs typically ranging from $5 to $20 [6]. By contrast, the Flow device carries a one-time price tag of $500 to $800, with no ongoing medication costs — a calculus that could favor the device over years of SSRI prescriptions for some patients, but represents a steep upfront barrier for low-income populations who already use antidepressants at higher rates [1][6].

What the Clinical Evidence Actually Shows

Transcranial direct current stimulation, or tDCS, works by delivering a low-intensity electrical current (typically 0.5 to 2 milliamperes) through electrodes placed on the scalp, targeting the dorsolateral prefrontal cortex — a brain region implicated in mood regulation [7]. The technique has been studied for over two decades, generating more than 29,000 published papers, with research output peaking at 4,521 papers in 2025 [8].

Source: OpenAlex

Data as of Jan 1, 2026CSV

The clinical evidence, however, is less voluminous than that publication count suggests. A 2021 meta-analysis of 27 randomized controlled trials found active tDCS superior to sham stimulation with a low-to-moderate effect size (Hedges' g = 0.46), and response rates of 34% for active tDCS versus 19% for sham [9]. An individual patient data meta-analysis reported similar findings: response of 30.9% versus 18.9%, with a number needed to treat of 9 [10].

Source: Meta-analyses (BJPsych, Nature Medicine)

Data as of Jan 1, 2024CSV

Those numbers should be placed in context. SSRIs typically produce response rates around 50% in clinical trials [11]. The FDA itself characterized the benefit of the Flow device as "modest" but "sufficient to outweigh its probable risk" [1].

The pivotal trial behind the FDA approval — a Phase 2 study published in Nature Medicine in 2024 — enrolled 174 participants randomized to active or sham tDCS over 10 weeks. Active treatment produced a 9.41-point improvement on the Hamilton Depression Rating Scale compared to 7.14 points for sham (p = 0.012) [12]. The trial was funded by Flow Neuroscience [1][12].

The Lancet Trial That Complicates the Story

The most rigorous independent test of tDCS for depression to date yielded a starkly different result. The DepressionDC trial, published in The Lancet in 2023, was a triple-blind, sham-controlled study across eight hospitals in Germany. It enrolled 160 patients already taking SSRIs and tested whether adding tDCS would improve outcomes [13].

It did not. The active tDCS group improved by 8.2 points on the Montgomery-Åsberg Depression Rating Scale; the sham group improved by 8.0 points — a statistically meaningless difference of 0.3 points [13]. No secondary outcomes reached significance, including response rates, remission rates, and functioning at 18-week and 30-week follow-up [13]. Notably, the active tDCS group experienced significantly more adverse events (60%) than the sham group (43%) [13].

Medscape ran its coverage under the headline "End of the Road for tDCS as an Adjunct in Major Depression?" [14]. The trial's implications are specific but important: tDCS does not appear to add benefit on top of SSRIs. Whether it works as a standalone replacement remains a separate, less thoroughly tested question.

The Placebo Problem

Brain stimulation research faces a distinctive methodological challenge: participants can often tell whether they are receiving active or sham treatment. Tingling, warmth, or mild discomfort at the electrode site can function as an unintentional unblinding cue, inflating the apparent benefit of active stimulation [15].

Research published in Scientific Reports in 2024 found that participants' expectations about whether they were receiving real tDCS were "significantly related to the placebo effect" [15]. A separate analysis found that tDCS may actually reinforce neural networks activated by placebo expectations, meaning the technology could amplify its own placebo response [16].

A p-curve analysis of cognitive tDCS studies — a statistical method for detecting whether a body of research contains genuine effects or just noise — found "no evidence that the studies had evidential value," with estimated statistical power of approximately 14% [17]. While this analysis focused on cognitive rather than depression outcomes, it underscores a broader pattern: many tDCS studies are substantially underpowered, making it difficult to distinguish real effects from statistical artifacts.

Robert Reinhart, a neuroscientist at Boston University, told Scientific American that tDCS "has been studied for more than two decades, and the evidence base is mixed," cautioning that "more work is needed to establish tDCS's long-term efficacy" [1].

Who Benefits — and Who Doesn't

The evidence suggests tDCS works best in a specific, narrow population: patients with mild to moderate major depressive disorder who have not already failed multiple antidepressant trials.

Treatment-resistant depression (TRD) — defined as failure to respond to two or more antidepressant medications — is associated with dramatically lower tDCS efficacy. An individual patient data meta-analysis found TRD patients were more than 60% less likely to benefit from tDCS compared to non-TRD patients [10]. The FDA label for the Flow device explicitly excludes patients "considered treatment refractory to medication" [2].

Dose also matters substantially: patients receiving a total charge of 43.2 coulombs (12 sessions of 2 milliampere stimulation for 30 minutes each) were more than five times more likely to respond than those receiving even slightly lower doses [10]. This suggests that adherence to a precise protocol is critical — a concern when treatment moves from supervised clinical settings to patients' living rooms.

Intriguingly, some evidence suggests bipolar depression patients may respond better to tDCS than those with unipolar depression, though this finding requires further replication [10]. Anxiety-adjacent conditions have shown mixed results in transdiagnostic analyses [18].

Despite these population-specific findings, the marketing of consumer brain stimulation devices has not always reflected such nuance. Flow Neuroscience's Halo brand — which uses what the company describes as "identical tDCS hardware" — is already available direct-to-consumer in the United States without a prescription, and the Flow device itself is sold without prescription in the UK and EU [1][19].

Following the Money

The financial dynamics surrounding at-home brain stimulation merit scrutiny. Flow Neuroscience has raised $11.9 million in venture funding across four rounds, with investors including Khosla Ventures and HAX [19]. The company funded the Phase 2 trial that served as the basis for FDA approval [1][12].

This is not unusual in medical device regulation — companies routinely fund their own pivotal trials. But the pattern becomes concerning when the only large independent trial (DepressionDC) found no benefit, while the company-sponsored trial did [1][13]. The discrepancy may be explained by differences in study design — the Lancet trial tested tDCS as an add-on to SSRIs, while the Flow trial tested it as a standalone or adjunctive treatment with different parameters — but the alignment of funding and favorable results is a pattern that warrants transparency.

In 2021, Flow Neuroscience acquired Halo Neuroscience, a company that had marketed brain stimulation headsets to athletes and consumers [19]. The Halo device remains on the market in the U.S. as a consumer wellness product, operating outside the FDA's prescription-device framework. This dual positioning — clinical device in one market, consumer gadget in another, using the same hardware — raises questions about whether the regulatory boundaries between medical treatment and wellness product are being deliberately blurred.

The broader financial stakes are significant. The global antidepressant market exceeds $16 billion annually [5]. Even a modest shift of patients from SSRIs to brain stimulation could redirect billions in pharmaceutical revenue — creating strong incentives for both device companies seeking market entry and pharmaceutical companies seeking to defend their position.

The Long-Term Data Gap

Perhaps the most significant gap in the evidence is the absence of longitudinal data. No published tDCS study has tracked depression outcomes beyond 30 weeks, and most pivotal trials measure endpoints at 6 to 10 weeks [12][13].

The closest analogy comes from deep brain stimulation (DBS), a more invasive procedure involving surgically implanted electrodes. DBS studies have shown sustained benefit over eight years of continuous stimulation — but also rapid relapse within approximately two weeks when stimulation is discontinued, including return of suicidal ideation in some cases [20][21]. Three out of five patients in one discontinuation study relapsed during cessation of treatment [20].

While tDCS is a fundamentally different technology from DBS — non-invasive, lower intensity, targeting different neural circuits — the DBS discontinuation data raises an uncomfortable question: does brain stimulation treat depression, or does it merely suppress symptoms as long as current flows? If the latter, patients who abandon SSRIs for tDCS may face recurring depressive episodes without the pharmacological safety net they gave up.

No researcher has yet published data on relapse rates for patients who substituted tDCS for antidepressants over periods longer than 12 months. This is a critical gap given that depression is frequently a chronic, recurring condition.

The Regulatory Gray Zone

The FDA's approval of the Flow FL-100 as a prescription device represents one end of the regulatory spectrum. At the other end sit numerous consumer brain stimulation devices marketed for "wellness," "focus," or "cognitive enhancement" that make no explicit medical claims and therefore fall outside FDA oversight [22].

The number of these devices is difficult to pin down precisely. A 2023 regulatory review noted that tDCS devices operating below certain output thresholds can be classified as "limited output transcranial electrical stimulation" (LOTES) devices, a category the FDA has treated with a lighter regulatory touch [22]. Several consumer tDCS devices are available online for under $200, with user communities sharing electrode placement guides and stimulation protocols on forums and social media [22].

The gap between a $500-$800 FDA-approved prescription device with clinical trial backing and a $100 consumer headset with none creates a two-tier system. Patients who cannot afford the prescription device — or who cannot access a prescribing clinician — may turn to unregulated alternatives, guided by anecdotal evidence rather than clinical data.

Second-Order Consequences

If at-home brain stimulation scales widely, the ripple effects extend beyond individual patients.

For psychiatry's workforce: The United States already faces a severe shortage of psychiatrists, with projections of tens of thousands of unfilled positions [23]. A device-based treatment that requires less clinical oversight could, in theory, expand access for underserved populations. But it could also reduce demand for the psychiatric evaluations and medication management visits that sustain many practices — further destabilizing a fragile workforce pipeline.

For pharmaceutical companies: With SSRIs commanding roughly $9 billion in annual revenue globally [5], even a 5-10% migration of patients to brain stimulation would represent hundreds of millions in lost sales. Pharmaceutical companies have historically responded to competitive threats through lobbying, physician education campaigns, and strategic pricing — dynamics likely to intensify if tDCS adoption grows.

For patients: The most immediate risk is premature medication discontinuation. Patients who read headlines about FDA-approved brain stimulation and conclude that their SSRI is unnecessary may stop medication without clinical guidance, facing withdrawal symptoms and depressive relapse. The FDA's decision to require a prescription for the Flow device provides some guardrail, but the existence of unregulated consumer alternatives undermines it.

Where the Evidence Stands

The honest summary is this: tDCS for depression has a real but modest evidence base. It outperforms sham stimulation in most (not all) trials, with effect sizes in the low-to-moderate range. It appears to work best in patients with mild-to-moderate, non-treatment-resistant depression — a population that also tends to respond well to SSRIs, therapy, and exercise. It does not appear to add benefit on top of SSRIs. Its long-term efficacy is unknown. Its largest independent trial was negative. And the company that makes the only FDA-approved device funded the trial that got it approved.

None of this means tDCS is useless. For patients who cannot tolerate SSRI side effects — sexual dysfunction, weight gain, emotional blunting — a non-pharmacological option with a modest evidence base and a mild side-effect profile may represent a genuine improvement in quality of life. For the 30-40% of depression patients who do not respond adequately to first-line antidepressants, additional tools in the treatment arsenal matter.

But the framing of at-home brain stimulation as a replacement for antidepressants — rather than a supplement, and one with significant limitations — risks overstating the evidence and understating the stakes for the roughly 30 million Americans living with depression [3][4]. The question is not whether tDCS has potential. It is whether that potential is being marketed ahead of the science.